Taletrectinib: What the latest research means for people living with ROS1-positive lung cancer

10 minutes ago

7 min read

For people living with ROS1-positive lung cancer, treatment options have grown significantly over the past decade. One of the most recent additions, taletrectinib, is designed to address many of the challenges patients face, including brain metastases and resistance to earlier therapies. New data presented at the 2026 American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) Annual Meetings continue to build our understanding of how this next-generation targeted therapy performs in both newly diagnosed and previously treated patients.

Receiving a diagnosis of ROS1-positive non-small cell lung cancer (NSCLC) can feel overwhelming. Along with learning about an unfamiliar cancer, patients are often introduced to a new vocabulary filled with biomarker testing, targeted therapies, tyrosine kinase inhibitors (TKIs), and treatment sequencing.

Fortunately, advances in precision medicine have dramatically changed the outlook for many people with ROS1-positive lung cancer.

Rather than relying solely on chemotherapy, patients today have multiple targeted therapies designed specifically to block the abnormal ROS1 fusion protein that drives cancer growth. One of the newest of these therapies is taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI) that received FDA approval in June 2025 for adults with locally advanced or metastatic ROS1-positive NSCLC.

Researchers continue to learn more about taletrectinib through the TRUST-I and TRUST-II clinical trials, and new findings presented at AACR and ASCO 2026 offer encouraging news for both newly diagnosed patients and those whose cancer has already been treated with another ROS1 inhibitor.

What makes taletrectinib different?

Like other ROS1 TKIs, taletrectinib works by blocking the abnormal ROS1 fusion protein that fuels cancer growth.

However, it was designed with two particularly important goals in mind.

First, researchers wanted a drug that could effectively reach and control cancer in the brain. Brain metastases remain one of the greatest challenges facing people with ROS1-positive lung cancer, making central nervous system (CNS) activity a critical feature of any targeted therapy.

Second, taletrectinib was developed to address one of the most common resistance mutations that develops after treatment with an earlier ROS1 TKI: G2032R. This mutation can make cancer resistant to several first-generation treatments, leaving patients with fewer treatment options. Laboratory studies suggested taletrectinib could retain activity against this mutation, alongside the activity in the CNS, providing the rationale for evaluating taletrectinib in both TKI-naïve and previously treated patients.

The TRUST-I and TRUST-II clinical trials

Much of what we know about taletrectinib comes from two Phase 2 clinical trials.

TRUST-I enrolled patients in China, while TRUST-II expanded globally to include patients from North America, Europe, and the Asia-Pacific region. Although conducted separately, the studies were intentionally designed in similar ways, allowing researchers to combine their results and gain a more complete understanding of the drug's performance.

Together, these studies evaluated adults with locally advanced or metastatic ROS1-positive NSCLC, including patients receiving their first ROS1-targeted therapy, as well as those who had previously been treated with another ROS1 inhibitor.

The latest efficacy results for patients who had not previously received a ROS1 TKI were presented at the 2026 AACR Annual Meeting. You can view the full presentation here:

https://nuvationbio.com/publications/aacr-2026-oral-bazhenova/

Encouraging results for newly diagnosed patients

Among patients receiving their first ROS1-targeted therapy, taletrectinib demonstrated impressive and durable responses.

Across the pooled analysis of TRUST-I and TRUST-II, approximately 90% of patients experienced tumor shrinkage, with many responses lasting years rather than months. Researchers also reported a median progression-free survival of approximately 46 months, meaning many patients remained free from disease progression for nearly four years after starting treatment. Overall survival has not yet been reached because many participants continue to benefit from therapy.

While every patient's experience is unique, these results suggest that taletrectinib can provide long-lasting disease control for many people beginning treatment for metastatic ROS1-positive lung cancer.

Activity in the brain

One of the most important findings continues to be taletrectinib's activity against brain metastases.

Because ROS1-positive lung cancer frequently spreads to the brain, physicians increasingly prioritize therapies capable of crossing the blood-brain barrier and controlling disease within the central nervous system.

In both TRUST-I and TRUST-II, patients with measurable brain metastases experienced meaningful intracranial responses, reinforcing taletrectinib's ability to treat disease both inside and outside the brain. Researchers carefully evaluated these responses in patients who had not recently received brain radiation, allowing them to better isolate the drug's true CNS activity.

This is particularly meaningful because controlling disease in the brain has become one of the most important considerations when selecting a ROS1 targeted therapy. A treatment that works both throughout the body and within the central nervous system can help reduce the need for additional local therapies such as radiation while maintaining quality of life.

Can taletrectinib help after another ROS1 inhibitor?

Treatment sequencing remains one of the biggest questions facing patients and oncologists.

Eventually, many cancers develop resistance to their initial ROS1 inhibitor. The challenge then becomes identifying the next therapy most likely to control the disease.

The TRUST studies also included patients previously treated with another ROS1 TKI and had their cancer spread after their first treatment—most commonly crizotinib, which was the standard first-line therapy for many years.

Cancer that has spread following initial treatment is often more difficult to manage. Although response rates were lower than those seen in newly diagnosed patients, researchers still observed meaningful clinical benefit for taletrectinib in patients who had been treated with a prior ROS1 TKI. More than half of previously treated patients experienced tumor shrinkage, with many maintaining disease control for months after beginning taletrectinib. These findings suggest taletrectinib may remain an effective option after progression on earlier-generation ROS1 inhibitors.

Researchers also presented early experience in a small group of patients previously treated with entrectinib. Although only ten patients were included, approximately 80% experienced a response, with evidence of continued activity in the brain. Because of the small sample size, larger studies will be needed to better understand these results, but the early findings are encouraging.

Additional results focused specifically on patients previously treated with another ROS1 inhibitor were presented at AACR 2026 and can be viewed here:

https://nuvationbio.com/publications/aacr-2026-poster-liu/

Looking beyond tumor response

While response rates and progression-free survival are important, they don't tell the entire story.

Patients often ask different questions:

Will I still be able to work?
Will I be able to think clearly?
Will I still feel like myself?

These questions were addressed through patient-reported outcomes presented at the 2026 ASCO Annual Meeting.

Participants regularly completed surveys describing their own quality of life while receiving taletrectinib. Researchers found that most patients maintained—or even improved—their overall quality of life throughout treatment. Cognitive function also improved or remained stable over time, an encouraging finding for patients receiving long-term therapy.

Researchers also reported improvements or stability in symptoms commonly associated with lung cancer, including cough, shortness of breath, fatigue, and pain. Rather than simply controlling tumors, the treatment allowed many patients to continue living well during therapy.

For many patients, these findings may be just as meaningful as traditional clinical trial endpoints. Living longer is important—but so is maintaining independence, cognitive function, and the ability to continue enjoying everyday life.

The complete patient-reported outcomes poster from ASCO 2026 is available here:

https://nuvationbio.com/publications/asco-2026-poster-elamin/

Understanding the side effects

Every cancer treatment has side effects, and taletrectinib is no exception. However, one of the themes emphasized during our discussion with the Nuvation Bio clinical team was the importance of understanding how side effects affect patients—not simply how they are categorized in clinical trials.

The most common treatment-related finding was an increase in liver enzymes detected during routine blood tests. Importantly, these laboratory changes often occurred without patients feeling ill, and only a small percentage required dose reductions or discontinuation because of liver-related side effects.

Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and constipation, were also common, but they typically appeared early in treatment and were generally manageable with supportive medications and dose adjustments when needed. Researchers emphasized that preparing patients before treatment begins can often make these symptoms easier to manage.

Another important observation involved dizziness, a side effect sometimes associated with ROS1-targeted therapies. In the TRUST studies, dizziness was usually mild, occurred later in treatment, and did not impact patients’ ability to stay on therapy.

One discussion during our interview was especially noteworthy. Clinical trials classify side effects using standardized "grades," but those grades don't always reflect how symptoms impact daily life. For example, a side effect categorized as "Grade 2" may still significantly interfere with work, family responsibilities, or quality of life. That reminder reinforces why patient-reported outcomes are becoming such an important part of cancer research, they provide a fuller picture of the treatment experience beyond laboratory values and physician assessments.

Looking ahead

The encouraging results from TRUST-I and TRUST-II have already helped establish taletrectinib as an important treatment option for metastatic ROS1-positive lung cancer. But researchers are now asking an even bigger question:

What if we begin treatment before metastatic disease ever develops?

That question is now being explored in the TRUST-IV clinical trial, which is studying whether taletrectinib can reduce the risk of recurrence in patients with early-stage ROS1-positive lung cancer after surgery.

As molecular testing becomes more common and targeted therapies continue moving into earlier stages of disease, the future of ROS1 treatment is evolving rapidly.

To learn more about the TRUST-IV clinical trial, including who may be eligible and how the study is designed, read our companion article: A New Chapter for ROS1-Positive Lung Cancer: Understanding the TRUST-IV Trial

You can also view the official TRUST-IV Trial-in-Progress poster presented at ASCO 2026 here:

https://nuvationbio.com/publications/asco-2026-poster-spira/

What this means for patients

Taletrectinib represents more than another treatment option—it reflects how far precision medicine has come for the ROS1 community.

The latest data continue to reinforce several encouraging themes:

High response rates for patients starting their first ROS1-targeted therapy
Meaningful activity against brain metastases
Continued benefit for many patients previously treated with another ROS1 inhibitor
Preservation of quality of life and cognitive function during treatment
A manageable safety profile that is now supporting studies in earlier-stage disease

While research continues, these findings provide hope that patients with ROS1-positive lung cancer will have increasingly effective—and increasingly personalized—treatment options for years to come.